EXETER, N.H.--(BUSINESS WIRE)--CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX) today announced that its development and commercialization partner, Serenity Pharmaceuticals, has reported initiation of a Phase II clinical study of an intranasal drug candidate delivered using CPEX’s patented drug delivery platform technology for an undisclosed urology indication. The study is a multi-center study expected to be completed by the end of 2008.
